Treatment of hepatitis C in hemodialysis patients using pegylated interferon alpha-2a in Turkey.

Hepatitis C virus (HCV) is prevalent in renal insufficient patients. The aim of the present study was to evaluate the efficacy and tolerability of pegylated interferon alpha-2a (peg-IFN-alpha-2a) among these patients.
Among 437 patients within total hemodialysis population in hemodialysis units, in total 83 patients (19.0%) were anti-HCV positive and of these 83 patients, 33 (39.7%) were HCV-RNA positive. Treatment was initiated in 33 patients who had chronic HCV infection. All patients were found to be HCV-RNA positive. During treatment, peg-IFN-alpha-2a (40 kDa), 135 microg/week was used on these 33 patients.
Twenty-six (78.8%) of the 33 patients enrolled in the study completed the treatment. Two patients (6.0%) did not complete treatment because they had serious adverse events such as anemia and thrombocytopenia. At the onset of treatment, while all of 26 patients were HCV RNA positive, HCV RNA turned to negative in all 26 patients 3 months after treatment.
At the end of the study, peg-IFN-alpha-2a treatment of patients with chronic hepatitis C on maintenance hemodialysis may improve prognosis and their quality of life.
AuthorsSukran Kose, Alp Gurkan, Fatih Akman, Mehmet Kelesoglu, Ufuk Uner
JournalJournal of gastroenterology (J Gastroenterol) Vol. 44 Issue 4 Pg. 353-8 ( 2009) ISSN: 0944-1174 [Print] Japan
PMID19277451 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Antiviral Agents
  • Interferon-alpha
  • RNA, Viral
  • Recombinant Proteins
  • peginterferon alfa-2a
  • Polyethylene Glycols
  • interferon alfa-2a
  • Adult
  • Aged
  • Anemia (chemically induced)
  • Antiviral Agents (adverse effects, therapeutic use)
  • Female
  • Follow-Up Studies
  • Hepacivirus (drug effects, genetics)
  • Hepatitis C, Chronic (complications, drug therapy)
  • Humans
  • Interferon-alpha (adverse effects, therapeutic use)
  • Male
  • Middle Aged
  • Polyethylene Glycols (adverse effects, therapeutic use)
  • Prognosis
  • Quality of Life
  • RNA, Viral (blood)
  • Recombinant Proteins
  • Renal Dialysis
  • Thrombocytopenia (chemically induced)
  • Treatment Outcome
  • Turkey (epidemiology)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: